Kis és közepes kockázatú prosztatarákos betegek sztereotaxiás sugárkezelése CyberKnife gyorsítóval: korai radiogén mellékhatások

Translated title of the contribution: Stereotactic body radiation therapy with CyberKnife accelerator for low- and intermediate risk prostate cancer

Kliton Jorgo, Péter Ágoston, Levente Jánváry, László Gesztesi, Gábor Stelczer, Gábor Kontra, T. Major, C. Polgár

Research output: Contribution to journalArticle

Abstract

We report implementation of stereotactic body radiotherapy (SBRT) for the treatment of early, localized prostate cancer patients, and acute side effects caused by radiation therapy. Between February 2018 and July 2018, 36 prostate cancer patients were treated with SBRT. Treatments were performed with "CyberKnife M6" linear accelerator. In low-risk patients 8 Gy was delivered to the prostate in each fraction. For intermediate risk, 8 Gy to the prostate and 6.5 Gy to the seminal vesicles were delivered by each fraction with a simultaneous integrated boost technique. A total of 5 fractions (total dose 40 Gy) were given every second working days. Acute radiogenic genitourinary (GU) and gastrointestinal (GI) side effects were assessed using the Radiation Therapy Oncology Group (RTOG) score. The duration of radiotherapy was 1 week and 3 days. The frequency of acute radiogenic side effects was as follows: GU grade 0: 13.9%, grade I: 30.6%, grade II: 52.8%, grade III: 2.7%. GI grade 0: 55.5%, grade I: 30.6%, grade II: 13.9%, grade III: 0%. Grade IV-V side effects were not observed. SBRT appears to be a safe and well tolerated treatment in patients with early stage, localized prostate cancer.

Original languageHungarian
Pages (from-to)52-59
Number of pages8
JournalMagyar onkologia
Volume63
Issue number1
Publication statusPublished - Mar 19 2019

Fingerprint

Radiosurgery
Prostatic Neoplasms
Radiotherapy
Prostate
Particle Accelerators
Radiation Oncology
Seminal Vesicles
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Kis és közepes kockázatú prosztatarákos betegek sztereotaxiás sugárkezelése CyberKnife gyorsítóval : korai radiogén mellékhatások. / Jorgo, Kliton; Ágoston, Péter; Jánváry, Levente; Gesztesi, László; Stelczer, Gábor; Kontra, Gábor; Major, T.; Polgár, C.

In: Magyar onkologia, Vol. 63, No. 1, 19.03.2019, p. 52-59.

Research output: Contribution to journalArticle

Jorgo, Kliton ; Ágoston, Péter ; Jánváry, Levente ; Gesztesi, László ; Stelczer, Gábor ; Kontra, Gábor ; Major, T. ; Polgár, C. / Kis és közepes kockázatú prosztatarákos betegek sztereotaxiás sugárkezelése CyberKnife gyorsítóval : korai radiogén mellékhatások. In: Magyar onkologia. 2019 ; Vol. 63, No. 1. pp. 52-59.
@article{91557ccd90e14f4ca84d1d08826ad6e6,
title = "Kis {\'e}s k{\"o}zepes kock{\'a}zat{\'u} prosztatar{\'a}kos betegek sztereotaxi{\'a}s sug{\'a}rkezel{\'e}se CyberKnife gyors{\'i}t{\'o}val: korai radiog{\'e}n mell{\'e}khat{\'a}sok",
abstract = "We report implementation of stereotactic body radiotherapy (SBRT) for the treatment of early, localized prostate cancer patients, and acute side effects caused by radiation therapy. Between February 2018 and July 2018, 36 prostate cancer patients were treated with SBRT. Treatments were performed with {"}CyberKnife M6{"} linear accelerator. In low-risk patients 8 Gy was delivered to the prostate in each fraction. For intermediate risk, 8 Gy to the prostate and 6.5 Gy to the seminal vesicles were delivered by each fraction with a simultaneous integrated boost technique. A total of 5 fractions (total dose 40 Gy) were given every second working days. Acute radiogenic genitourinary (GU) and gastrointestinal (GI) side effects were assessed using the Radiation Therapy Oncology Group (RTOG) score. The duration of radiotherapy was 1 week and 3 days. The frequency of acute radiogenic side effects was as follows: GU grade 0: 13.9{\%}, grade I: 30.6{\%}, grade II: 52.8{\%}, grade III: 2.7{\%}. GI grade 0: 55.5{\%}, grade I: 30.6{\%}, grade II: 13.9{\%}, grade III: 0{\%}. Grade IV-V side effects were not observed. SBRT appears to be a safe and well tolerated treatment in patients with early stage, localized prostate cancer.",
author = "Kliton Jorgo and P{\'e}ter {\'A}goston and Levente J{\'a}nv{\'a}ry and L{\'a}szl{\'o} Gesztesi and G{\'a}bor Stelczer and G{\'a}bor Kontra and T. Major and C. Polg{\'a}r",
year = "2019",
month = "3",
day = "19",
language = "Hungarian",
volume = "63",
pages = "52--59",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Kis és közepes kockázatú prosztatarákos betegek sztereotaxiás sugárkezelése CyberKnife gyorsítóval

T2 - korai radiogén mellékhatások

AU - Jorgo, Kliton

AU - Ágoston, Péter

AU - Jánváry, Levente

AU - Gesztesi, László

AU - Stelczer, Gábor

AU - Kontra, Gábor

AU - Major, T.

AU - Polgár, C.

PY - 2019/3/19

Y1 - 2019/3/19

N2 - We report implementation of stereotactic body radiotherapy (SBRT) for the treatment of early, localized prostate cancer patients, and acute side effects caused by radiation therapy. Between February 2018 and July 2018, 36 prostate cancer patients were treated with SBRT. Treatments were performed with "CyberKnife M6" linear accelerator. In low-risk patients 8 Gy was delivered to the prostate in each fraction. For intermediate risk, 8 Gy to the prostate and 6.5 Gy to the seminal vesicles were delivered by each fraction with a simultaneous integrated boost technique. A total of 5 fractions (total dose 40 Gy) were given every second working days. Acute radiogenic genitourinary (GU) and gastrointestinal (GI) side effects were assessed using the Radiation Therapy Oncology Group (RTOG) score. The duration of radiotherapy was 1 week and 3 days. The frequency of acute radiogenic side effects was as follows: GU grade 0: 13.9%, grade I: 30.6%, grade II: 52.8%, grade III: 2.7%. GI grade 0: 55.5%, grade I: 30.6%, grade II: 13.9%, grade III: 0%. Grade IV-V side effects were not observed. SBRT appears to be a safe and well tolerated treatment in patients with early stage, localized prostate cancer.

AB - We report implementation of stereotactic body radiotherapy (SBRT) for the treatment of early, localized prostate cancer patients, and acute side effects caused by radiation therapy. Between February 2018 and July 2018, 36 prostate cancer patients were treated with SBRT. Treatments were performed with "CyberKnife M6" linear accelerator. In low-risk patients 8 Gy was delivered to the prostate in each fraction. For intermediate risk, 8 Gy to the prostate and 6.5 Gy to the seminal vesicles were delivered by each fraction with a simultaneous integrated boost technique. A total of 5 fractions (total dose 40 Gy) were given every second working days. Acute radiogenic genitourinary (GU) and gastrointestinal (GI) side effects were assessed using the Radiation Therapy Oncology Group (RTOG) score. The duration of radiotherapy was 1 week and 3 days. The frequency of acute radiogenic side effects was as follows: GU grade 0: 13.9%, grade I: 30.6%, grade II: 52.8%, grade III: 2.7%. GI grade 0: 55.5%, grade I: 30.6%, grade II: 13.9%, grade III: 0%. Grade IV-V side effects were not observed. SBRT appears to be a safe and well tolerated treatment in patients with early stage, localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85063275587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063275587&partnerID=8YFLogxK

M3 - Article

C2 - 30889621

AN - SCOPUS:85063275587

VL - 63

SP - 52

EP - 59

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -